Detection of ‘antiphospholipid’ antibodies: a single chromogenic assay of thrombin generation sensitively detects lupus anticoagulants, anticardiolipin antibodies, plus antibodies bindingβ2-glycoprotein I and prothrombin
Open Access
- 1 June 2001
- journal article
- Published by Oxford University Press (OUP) in Clinical and Experimental Immunology
- Vol. 124 (3) , 502-508
Abstract
The diagnosis of the antiphospholipid syndrome (APS) requires both a typical clinical event plus a persistently positive test in an assay for either anticardiolipin (aCL) antibodies or a lupus anticoagulant (LA). Enzyme linked immunosorbent assays (ELISA) specific for autoantibodies against β2‐glycoprotein I (β2GPI) or prothrombin are also used, but none of the tests are adequately sensitive or specific. A chromogenic assay was developed that measures the effect of test antibody or plasma samples on in vitro thrombin formation. It is able to detect both LA and β2GPI‐dependent aCL antibodies and may have greater specificity for APS than currently available tests. Using this method various monoclonal antibodies (MoAbs) were examined, from mice immunized with β2GPI, mice with a spontaneous animal model of APS, and from three humans with APS. Plasma and affinity purified antibodies from patients with APS and control groups were also examined. Thrombin inhibition was more sensitive to perturbation by MoAbs than a combination of tests for LA (P < 0·05) and at lower antibody concentrations (12·5 µg/ml versus 100 µg/ml). There was a significant correlation between inhibition of thrombin generation and the level of MoAb reactivity to β2GPI (r = 0·90; P < 0·001) but not to CL (r = 0·06; P = 0·76). Plasma and affinity purified antibodies from patients with APS also inhibited thrombin generation, and significantly more so than patients with aPL from causes other than APS. APS patient samples showed thrombin inhibition in the presence of anti‐β2GPI or antiprothrombin antibodies. All MoAbs binding β2GPI showed inhibition of thrombin generation, while MoAbs binding domain I of β2GPI had more LA effect.Keywords
This publication has 33 references indexed in Scilit:
- Current Insights into the “Antiphospholipid” Syndrome: Clinical, Immunological, and Molecular Aspects1998
- Immunology of the antiphospholipid antibody syndromeArthritis & Rheumatism, 1996
- Comparison of an enzyme‐linked immunosorbent assay for antibodies to β2‐glycoprotein I and a conventional anticardiolipin immunoassayArthritis & Rheumatism, 1996
- β2‐Glycoprotein i reactivity of monoclonal anticardiolipin antibodies from patients with the antiphospholipid syndromeArthritis & Rheumatism, 1994
- Anticardiolipin Antibodies and β2-Glycoprotein IClinical Immunology and Immunopathology, 1994
- Association of anti-β2 glycoprotein I antibodies with lupus-type circulating anticoagulant and thrombosis in systemic lupus erythematosusThe American Journal of Medicine, 1992
- A Phospholipid-β2-Glycoprotein I Complex Is an Antigen for Anticardiolipin Antibodies Occurring in Autoimmune Disease But Not with InfectionLupus, 1992
- Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactorThe Lancet, 1990
- Amidolytic assay for procoagulant activity of lymphoid and tumor cellsJournal of Immunological Methods, 1986
- Thrombosis, abortion, cerebral disease, and the lupus anticoagulant.BMJ, 1983